Italia markets open in 5 hours 57 minutes

Biophytis S.A. (0D1W.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,5739-0,0011 (-0,19%)
Alla chiusura: 11:44AM BST

Biophytis S.A.

Sorbonne University
Bâtiment A 4ème étage 4 place Jussieu Cedex 05
Paris 75005
France
33 1 44 27 23 00
https://www.biophytis.com

Settore/i
Settore
Impiegati a tempo pieno22

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Stanislas Veillet Ph.D.Chairman of the Board & CEO349kN/D1965
Mr. Nicolas FellmannChief Financial OfficerN/DN/D1968
Mr. Waly Dioh Ph.D.Chief Clinical Operating OfficerN/DN/D1969
Dr. Pierre J. Dilda Ph.D.Chief Scientific OfficerN/DN/D1970
Dr. Rene LafontScientific Advisor & Member of Scientific Advisory BoardN/DN/D1946
Dr. Rob van Maanen FFPM, M.B.A., M.D.Chief Medical OfficerN/DN/D1971
Mr. Edouard BiethChief Business OfficerN/DN/D1980
Ms. Chiara BaccelliChief Pharmaceutical Operations Officer & Quality Assurance DirectorN/DN/DN/D
Ms. _ TeylanFinancial ControllerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di Biophytis S.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.